Compare Freshworks Inc (FRSH) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs IDEXX Laboratories, Inc. — how do they compare? Freshworks Inc trades at $11.66 (market cap $3.31B), while IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 14× Freshworks Inc's market cap, and Freshworks Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| FRSH | IDXX | |
|---|---|---|
Market Cap | $3.31B | $46.22B |
Sector | Technology | Health |
52-Week High | $13.97 | $766.68 |
52-Week Low | $6.88 | $526.44 |
Enterprise Value | $2.68B | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $11.67, down 2.59% on the day, with a bullish technical signal from moving averages but a neutral RSI. The company reported strong Q2 2026 results, beating earnings estimates with $0.17 EPS, and achieved its first quarter of GAAP profitability in 2026. Revenue growth remains robust at 16% year-over-year, supported by strength in its employee experience (EX) segment, which now represents 60% of ARR.
The outlook is positive, with a consensus price target of $16.50 implying significant upside. Key opportunities include AI monetization and public sector expansion via FedRAMP progress. Risks include high valuation multiples like a 40.22 EV/EBITDA and competitive pressure in the SaaS sector. Analyst sentiment is evenly split between Buy and Hold ratings.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
